1548 ET -- Revvity still has areas of continued end-market softness, as its slower-than-expected instrument recovery led management to reduce its guidance for the year, Baird analysts say in a research note. The provider of research-and-discovery, testing and other services to the medical industry also posted a mixed revenue performance as consumer spending on instruments continues to be constrained, particularly in China. Still, the analysts say they remain constructive on the medium-term setup at the current valuation. Shares rise 0.5% to $125.38. (sabela.ojea@wsj.com)

(END) Dow Jones Newswires

November 05, 2024 15:51 ET (20:51 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.